Frontiers in Genome Editing

OCT 13, 2026 · JOURNAL ARTICLE

Engineering next-generation CAR-NK cells for hematological malignancies: genome editing, synthetic biology, and precision immunotherapy

Frontiers in Genome Editing

Chimeric antigen receptor (CAR)-based immunotherapy has transformed cancer treatment by enabling engineered immune cells to selectively recognize and eliminate malignant targets, w

SEP 30, 2026 · JOURNAL ARTICLE

Protocol for non-viral HDR-based CRISPR/Cas9 platform for small custom editing in primary T cells

Frontiers in Genome Editing

CRISPR/Cas9 enables precision gene editing via homology-directed repair (HDR) for mutation correction and disease modelling. Here we present a customizable T cell single nucleotide

SEP 30, 2026 · JOURNAL ARTICLE

Gene therapy for non-obstructive azoospermia: therapeutic avenues and translational pathway to clinical application

Frontiers in Genome Editing

Non-obstructive azoospermia (NOA) represents the most severe male infertility. Although microsurgical testicular sperm extraction combined with intracytoplasmic sperm injection off

SEP 18, 2026 · JOURNAL ARTICLE

A novel minimally humanized mouse model of aniridia for preclinical evaluation of CRISPR gene editing strategies

Frontiers in Genome Editing

Introduction Aniridia is a rare congenital vision-loss disorder primarily caused by variants in the paired box 6 ( PAX6 ) gene. Current treatments do not maintain vision long term,

SEP 10, 2026 · JOURNAL ARTICLE

Advancements in CRISPR-based in vivo gene therapy for hemophilia

Frontiers in Genome Editing

A narrative review article synthesizing current knowledge and future directions in CRISPR-based gene therapy for hemophilia, without reporting original empirical findings or clinical trial results.

SEP 10, 2026 · JOURNAL ARTICLE

Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders

Frontiers in Genome Editing

A structured literature review synthesizing current evidence on CRISPR-Cas9 therapeutic applications, identifying clinical advances, translational hurdles, and emerging alternatives without reporting original trial data or effect sizes.